Provided by Tiger Trade Technology Pte. Ltd.

INVESCO BIOTECHNOLOGY & GENOME ETF

98.68
+1.741.79%
Volume:128.25K
Turnover:12.62M
Market Cap:406.56M
PE:55.03
High:98.68
Open:97.34
Low:97.30
Close:96.94
52wk High:98.82
52wk Low:67.69
Shares:4.12M
Float Shares:4.12M
Volume Ratio:6.45
T/O Rate:3.11%
Dividend:1.55
Dividend Rate:1.57%
EPS(TTM):1.79
EPS(LYR):18.65
ROE:24.76%
ROA:0.08%
PB:1.64
PE(LYR):5.29

Loading ...

Amgen SVP, Chief Compliance Officer Nancy Grygiel Sells 2,970 Shares for $1.2 Million

Reuters
·
Aug 08

Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio

Reuters
·
Aug 08

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock is Tumbling.

Dow Jones
·
Aug 08

Grail announces FDA advisory committee meeting to review Galleri test PMA

TIPRANKS
·
Aug 07

Xenetic Biosciences Q2 Royalty Revenue Rises on Takeda Sublicense

Reuters
·
Aug 07

Sino Biopharmaceutical Stock Climbs 3.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 07

Biogen completes acquisition of RayThera

TIPRANKS
·
Aug 07

Biogen Completes Acquisition of RayThera

Reuters
·
Aug 07

Biogen Completes Acquisition of Raythera Inc.

THOMSON REUTERS
·
Aug 07

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Vortex Energy Study Confirms Major Salt Structure and New Target at Robinsons River

TIPRANKS
·
Aug 07

Biogen Extends Felzartamab Kidney Rejection Trial, Bolstering Long-Term Pipeline Story

TIPRANKS
·
Aug 07

Salesforce, UnitedHealth Share Losses Contribute to Dow's Nearly 150-Point Drop

Dow Jones
·
Aug 06

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

TIPRANKS
·
Aug 06

Royalty Pharma price target raised to $70 from $66 at Citi

TIPRANKS
·
Aug 06

Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million

Reuters
·
Aug 06

Exelixis Q2 Revenue Misses Analyst Estimates, Lowers 2026 Outlook

Reuters
·
Aug 06

Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge

Reuters
·
Aug 06

Tenaya Net Loss Widens to $43.39 Million in Q2 FY26; R&D Expenses Slip to $16.6 Million

Reuters
·
Aug 06

Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment

Reuters
·
Aug 06